The extended-release (ER) formulation encapsulates exenatide within biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres, which form a polymeric matrix that allows sustained drug release following SC administration [13, 14, 58]
The fact that over 90% of Retatrutide patients hit this marker suggests we are looking at a genuinely different level of efficacy
The bioavailability gap means that nasal doses cannot simply mirror standard retatrutide dosing protocols
The 60-day money-back guarantee functions as the risk-mitigation mechanism - the brand promises "no questions asked, refund every penny." Brand-stated
Gina: Well, no, they can fit in a pill
It produced 20.4% weight loss in the Phase 3 REDEFINE 1 trial and is not yet FDA-approved